Adjunct treatment to increase absorption and dispersion of other injected drugs

This indication describes a pharmacologic drug delivery modality rather than an intrinsic disease or pathological condition

This indication describes a pharmacologic drug delivery modality rather than an intrinsic disease or pathological condition It represents a clinical state of physical tissue resistance within the extracellular matrix of interstitial connective tissue—most frequently in subcutaneous or intramuscular compartments—where dense hyaluronic acid networks impede fluid movement and restrict the systemic or localized uptake of co-administered agents Used across diverse patient populations requiring subcut...

It represents a clinical state of physical tissue resistance within the extracellular matrix of interstitial connective tissue—most frequently in subcutaneous or intramuscular compartments—where dense hyaluronic acid networks impede fluid movement and restrict the systemic or localized uptake of co-administered agents Used across diverse patient populations requiring subcutaneous rehydration, regional anesthesia, biologic therapies, or management of drug extravasation, this intervention relies o...

It represents a clinical state of physical tissue resistance within the extracellular matrix of interstitial connective tissue—most frequently in subcutaneous or intramuscular compartments—where dense hyaluronic acid networks impede fluid movement and restrict the systemic or localized uptake of co-administered agents

Used across diverse patient populations requiring subcutaneous rehydration, regional anesthesia, biologic therapies, or management of drug extravasation, this intervention relies on temporary enzymatic cleavage of hyaluronan glycosaminoglycans to lower interstitial viscosity and enhance vascular and lymphatic permeability